Acquisitions
Acquisitions completed from the 2023 financial year are distributed among the group’s business areas as follows:
| Acquisitions | Time | Net Sales, SEKm* | Number of employees* | Business area |
|---|---|---|---|---|
| Emmat Medical Ltd, Great Britain | September, 2023 | 28 | 4 | Medtech |
| BonsaiLab, Spain | July, 2024 | 90 | 13 | Labtech |
| 118 | 17 | |||
| * Refers to conditions at the time of acquisition on a full-year basis. | ||||
On July 4, 2024, AddLife AB acquired all shares in the Spanish company BonsaiLab. BonsaiLab is a leading Spanish distributor in cell and molecular biology and provides a product portfolio of market-leading instruments and consumables in cell and molecular biology. The company has a turnover of approximately EUR 8m and has 13 employees.
The acquisition that was completed during the year has overall affected the group's net sales by SEK 23m, EBITA by SEK 5m, the operating profit by SEK 3m and the period's profit after tax by SEK 2m. The acquisition would have affected the group's net sales by an estimated SEK 78m, EBITA by SEK 15m, operating profit by SEK 11m and the year's profit after tax by SEK 8m if they had been implemented on January 1, 2024.
The assets and liabilities that were included in the completed acquisitions during the financial year 2024 amount, according to the preliminary and determined acquisition analyses, to the following:
| Fair value | Total |
|---|---|
| Intangible non-current assets | 56 |
| Other non-current assets | 0 |
| Inventories | 7 |
| Other current assets | 33 |
| Deferred tax liability/tax asset | -14 |
| Other liabilities | -25 |
| Acquired net assets | 57 |
| Goodwill | 68 |
| Consideration¹ | 125 |
| Less: cash and cash equivalents in acquired businesses | -10 |
| Contingent consideration not yet paid | -62 |
| Effect on the Group’s cash and cash equivalents | 53 |
| ¹ The consideration is stated excluding acquisition expenses. |
The goodwill that has arisen in connection with the acquisitions is due to the fact that the group's position in the current market is expected to be strengthened and to the knowledge that has been developed in the acquired companies. Transaction costs for acquisitions total SEK 2m and are reported in the item sales costs.
Revaluation of liabilities for contingent considerations related to previous acquisitions in the Medtech Business Area has resulted in an income of SEK 4m. During the interim period, these have been revalued and reported in other operating income. Contingent consideration amounting to SEK 42m has been paid during the interim period regarding BioConnect, Funksjonsutstyr, O'Flynn and JKLab, which were acquired in previous years.